The bone mass density in postmenopausal women using hormonal replacement therapy in relation to polymorphism in vitamin D receptor and estrogen receptor genes.
The aims of the study were as follows: (1) To identify the differences in spinal body mass density (BMD) in relation to polymorphism in vitamin D receptor (VDR) and estrogen receptor-alpha (ERalpha) genes in untreated women with postmenopausal osteoporosis. (2) To assess the efficacy of treatment in women with postmenopausal osteoporosis in relation to polymorphism in VDR and ERalpha genes. (3) To find the estradiol concentration necessary to protect bone tissue in patients with a given polymorphism in VDR and ERalpha genes.


METHODS
The study included 44 postmenopausal women with primary osteoporosis who used cyclic hormonal replacement therapy (HRT) for a year. The polymorphism of ERalpha and VDR genes were evaluated. We also determined the age, body mass index and spinal BMD before and after 12 months of administration the HRT.


RESULTS
We found a significant spinal BMD increase, what is connected with ERalpha genotype and both VDR and ERalpha genes. There is no such a correlation observed in polymorphism of VDR gene.


CONCLUSIONS
(1) There is no relationship between VDR and ERalpha genes polymorphism and the stage of osteoporosis related to the spinal BMD value before treatment. (2) The XX, PP or Bb markers or only X, P, B alleles are connected with a significant decrease of treatment efficacy. (3) Estradiol serum concentration before and during HRT is not dependent on the polymorphism of VDR and ERalpha genes.
Brodowska
Agnieszka
A
Department of Reproduction and Gynecology, Pomeranian Medical University of Szczecin, 71-010 Police, Siedlecka 2, Poland. fampiel@sci.pam.szczecin.p
Starczewski
Andrzej
A
Brodowski
Jacek
J
Szydłowska
Iwona
I
Nawrocka-Rutkowska
Jolanta
J
D000328:Adult; D000368:Aged; D015519:Bone Density / Q000187:drug effects / Q000235:genetics*; D004958:Estradiol / Q000008:administration & dosage; D047628:Estrogen Receptor alpha / Q000235:genetics*; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy / Q000503:physiopathology*; D011110:Polymorphism, Genetic; D018167:Receptors, Calcitriol / Q000235:genetics*
D047628:Estrogen Receptor alpha; D004967:Estrogens; D018167:Receptors, Calcitriol; D004958:Estradiol